Physician

Naurin Ehsan Ahmad, M.D.

According to 2025 Medicare claims, Naurin Ahmad, M.D. (NPI: 1215196316) practices dermatology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Rock Island, IL. This provider's primary affiliated billing organization is MEDICAL ARTS ASSOCIATES, LTD. (NPI: 1396724183; TIN: 362689597) and primary practice location at 61265-6812.

Ahmad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 971 traditional Medicare patients, billed 5,057 HCPCS/CPT codes, and received $185,845 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,589 prescription claims across 619 beneficiaries totaling $1,214,177 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 186 records totaling $111,092. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $170,474 to $1,214,177. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$140K$281K2015 Medicare payment: $280,899 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $227,092 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $192,938 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $207,220 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $231,566 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $197,582 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $233,874 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $208,043 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $193,363 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $185,845 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,3478,867$280,899
20161,0486,613$227,092
20171,0056,207$192,938
20181,0006,213$207,220
20191,0496,595$231,566
20209625,515$197,582
20211,0406,186$233,874
20221,0235,458$208,043
20239584,910$193,363
20249715,057$185,845

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$607K$1.2M2015 Drug cost: $170,474 (USD; Tot_Drug_Cst)2016 Drug cost: $232,597 (USD; Tot_Drug_Cst)2017 Drug cost: $308,241 (USD; Tot_Drug_Cst)2018 Drug cost: $383,966 (USD; Tot_Drug_Cst)2019 Drug cost: $464,177 (USD; Tot_Drug_Cst)2020 Drug cost: $523,567 (USD; Tot_Drug_Cst)2021 Drug cost: $596,584 (USD; Tot_Drug_Cst)2022 Drug cost: $991,754 (USD; Tot_Drug_Cst)2023 Drug cost: $895,436 (USD; Tot_Drug_Cst)2024 Drug cost: $1,214,177 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015357989$170,474
20163881,023$232,597
20173811,004$308,241
20184221,062$383,966
20194881,177$464,177
20204731,253$523,567
20215451,410$596,584
20225771,493$991,754
20235301,354$895,436
20246191,589$1,214,177

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths245276$74
11102Biopsy of related skin growth, first growth242278$61
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more647729$57
17000Destruction of precancer skin growth, 1 growth474587$34
17003Destruction of precancer skin growth, 2-14 growths3622,027$4

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa221,792$442,333
OtezlaApremilast621,770$253,240
Dupixent PenDupilumab461,232$175,405
Dupixent SyringeDupilumab26784$103,339
RinvoqUpadacitinib11330$71,174

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.186$111,092ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Naurin Ehsan Ahmad, M.D.?

Tedicare shows public-source Medicare data for Naurin Ehsan Ahmad, M.D. (NPI 1215196316), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Naurin Ehsan Ahmad, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Naurin Ehsan Ahmad, M.D.?

Naurin Ehsan Ahmad, M.D. is linked to MEDICAL ARTS ASSOCIATES, LTD. (billing NPI 1396724183) in the available physician profile data.

Does Naurin Ehsan Ahmad, M.D. have Open Payments data?

Naurin Ehsan Ahmad, M.D. has 186 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.